KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Moderate Buy” from Brokerages

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $29.1667.

Several equities research analysts have recently commented on the stock. Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Needham & Company LLC lifted their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Citizens Jmp decreased their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Tuesday, November 11th. Finally, Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $14.96 on Friday. KalVista Pharmaceuticals has a twelve month low of $7.83 and a twelve month high of $19.00. The stock’s 50 day moving average is $14.93 and its 200-day moving average is $13.69. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The firm has a market capitalization of $756.23 million, a price-to-earnings ratio of -3.79 and a beta of -0.14.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million for the quarter, compared to the consensus estimate of $6.03 million. Sell-side analysts forecast that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insider Transactions at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 7,294 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $16.51, for a total value of $120,423.94. Following the completion of the sale, the chief executive officer owned 424,520 shares in the company, valued at $7,008,825.20. This represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Paul K. Audhya sold 5,296 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the sale, the insider directly owned 131,831 shares of the company’s stock, valued at $1,773,126.95. The trade was a 3.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 31,329 shares of company stock worth $437,371 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the first quarter valued at about $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of KalVista Pharmaceuticals by 13.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,939 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of KalVista Pharmaceuticals by 3.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock valued at $3,923,000 after buying an additional 12,263 shares in the last quarter. Rhumbline Advisers boosted its holdings in KalVista Pharmaceuticals by 3.4% in the 1st quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company’s stock worth $611,000 after buying an additional 1,762 shares during the period. Finally, Whalen Wealth Management Inc. bought a new position in KalVista Pharmaceuticals in the 2nd quarter worth $124,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.